NASDAQ:ATEC Alphatec (ATEC) Stock Price, News & Analysis → Central Banks Preparing for US Dollar Collapse? (From Behind the Markets) (Ad) Free ATEC Stock Alerts $13.79 -0.01 (-0.07%) (As of 03/28/2024 ET) Add Compare Share Share Today's Range$13.74▼$14.1850-Day Range$12.80▼$16.7852-Week Range$8.66▼$19.14Volume1.60 million shsAverage Volume1.68 million shsMarket Capitalization$1.90 billionP/E RatioN/ADividend YieldN/APrice Target$23.63 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Alphatec alerts: Email Address Alphatec MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside71.3% Upside$23.63 Price TargetShort InterestBearish7.99% of Shares Sold ShortDividend StrengthN/ASustainability-1.67Upright™ Environmental ScoreNews Sentiment0.68Based on 11 Articles This WeekInsider TradingSelling Shares$3.53 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($1.10) to ($0.78) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.59 out of 5 starsMedical Sector95th out of 938 stocksSurgical & Medical Instruments Industry11th out of 95 stocks 3.5 Analyst's Opinion Consensus RatingAlphatec has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $23.63, Alphatec has a forecasted upside of 71.3% from its current price of $13.79.Amount of Analyst CoverageAlphatec has only been the subject of 4 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted7.99% of the outstanding shares of Alphatec have been sold short.Short Interest Ratio / Days to CoverAlphatec has a short interest ratio ("days to cover") of 6.9.Change versus previous monthShort interest in Alphatec has recently decreased by 2.48%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldAlphatec does not currently pay a dividend.Dividend GrowthAlphatec does not have a long track record of dividend growth. Previous Next 3.3 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAlphatec has received a 37.18% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Cervical implants", "Medical screws", and "Lumbar spinal stenosis treatment instruments" products. See details.Environmental SustainabilityThe Environmental Impact score for Alphatec is -1.67. Previous Next 3.2 News and Social Media Coverage News SentimentAlphatec has a news sentiment score of 0.68. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 11 news articles for Alphatec this week, compared to 3 articles on an average week.Search Interest21 people have searched for ATEC on MarketBeat in the last 30 days. This is an increase of 950% compared to the previous 30 days.MarketBeat Follows8 people have added Alphatec to their MarketBeat watchlist in the last 30 days. This is an increase of 60% compared to the previous 30 days. Previous Next 5.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Alphatec insiders have sold 667.76% more of their company's stock than they have bought. Specifically, they have bought $459,550.00 in company stock and sold $3,528,245.00 in company stock.Percentage Held by Insiders29.12% of the stock of Alphatec is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions66.35% of the stock of Alphatec is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Alphatec are expected to grow in the coming year, from ($1.10) to ($0.78) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Alphatec is -8.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Alphatec is -8.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAlphatec has a P/B Ratio of 24.19. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the MarketsCentral Banks Preparing for US Dollar Collapse?China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.Find out how you can protect yourself now >>> About Alphatec Stock (NASDAQ:ATEC)Alphatec Holdings, Inc., a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems. It also provides split-blade retractors; Sigma-ALIF Access System, a procedure-specific access system; spinal implants and fixation systems comprising NanoTec surface modifications, Calibrate PSX, and Invictus, as well as various standalone implants for height restoration and stabilization. In addition, the company provides biologics comprising 3D ProFuse Osteoconductive Bioscaffold for ease of handling and better endplate-to-endplate contact; AlphaGRAFT Demineralized Bone Matrix (DBM) comprising demineralized human tissues; AlphaGRAFT DBM Fibers comprising demineralized fibers; AlphaGRAFT Cellular Bone Matrix (CBM), a growth factor-enriched cellular bone matrix; AlphaGRAFT CBM that is delivered in granular, fiber, or structural form; BioCORE Moldable Bioactive Graft, a synthetic mineral-collagen composite matrix that can be molded to fit the bone defect; and Amnioshield Amniotic Tissue Barrier, an allograft for spinal surgical barrier applications. The company sells its products through a network of independent sales agents and direct sales representatives. Alphatec Holdings, Inc. was founded in 1990 and is headquartered in Carlsbad, California.Read More ATEC Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ATEC Stock News HeadlinesMarch 19, 2024 | insidertrades.comInsider Buying: Alphatec Holdings, Inc. (NASDAQ:ATEC) Director Acquires 15,000 Shares of StockMarch 11, 2024 | insidertrades.comAlphatec Holdings, Inc. (NASDAQ:ATEC) General Counsel Tyson Eliot Marshall Sells 9,225 SharesMarch 29, 2024 | Behind the Markets (Ad)Central Banks Preparing for US Dollar Collapse?China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.March 29, 2024 | americanbankingnews.comAlphatec (NASDAQ:ATEC) Given New $23.00 Price Target at Needham & Company LLCMarch 29, 2024 | americanbankingnews.comAlphatec Holdings, Inc. (NASDAQ:ATEC) Receives Consensus Rating of "Buy" from AnalystsMarch 28, 2024 | markets.businessinsider.comAnalysts Conflicted on These Healthcare Names: Alphatec Holdings (ATEC) and Viatris (VTRS)March 27, 2024 | finance.yahoo.comAlphatec Holdings, Inc.'s (NASDAQ:ATEC) Intrinsic Value Is Potentially 60% Above Its Share PriceMarch 25, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Alphatec Holdings (ATEC) and Regeneron (REGN)March 29, 2024 | Behind the Markets (Ad)Central Banks Preparing for US Dollar Collapse?China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.March 25, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Regeneron (REGN) and Alphatec Holdings (ATEC)March 21, 2024 | msn.com5 Stocks Hedge Funds Love and Analysts SupportMarch 21, 2024 | americanbankingnews.comAlphatec (NASDAQ:ATEC) Rating Reiterated by Canaccord Genuity GroupMarch 21, 2024 | americanbankingnews.comAlphatec (NASDAQ:ATEC) Price Target Raised to $22.00 at Needham & Company LLCMarch 21, 2024 | americanbankingnews.comAlphatec (NASDAQ:ATEC) Shares Gap Up Following Analyst UpgradeMarch 20, 2024 | markets.businessinsider.comAlphatec Holdings: Poised for Profitable Growth with Billion-Dollar Revenue Target by 2027March 20, 2024 | markets.businessinsider.comBuy Rating Affirmed on Alphatec Holdings Amid Strong Growth and Profitability TargetsMarch 20, 2024 | investorplace.comShhh! 7 Small-Cap Stocks That Can Double by 2025March 19, 2024 | americanbankingnews.comAlphatec Holdings, Inc. (NASDAQ:ATEC) Director Evan Bakst Acquires 15,000 Shares of StockMarch 15, 2024 | markets.businessinsider.comStifel Nicolaus Reaffirms Their Buy Rating on Alphatec Holdings (ATEC)March 13, 2024 | markets.businessinsider.comA Closer Look at 4 Analyst Recommendations For Alphatec HoldingsMarch 13, 2024 | markets.businessinsider.comCritical Insights From Alphatec Holdings Analyst Ratings: What You Need To KnowMarch 10, 2024 | investorplace.com3 Sexy Small-Cap Stocks to Add Sizzle to Your PortfolioMarch 5, 2024 | finance.yahoo.comAlphatec Holdings Inc CFO John Koning Sells 121,601 SharesMarch 1, 2024 | nasdaq.comAlphatec Holdings (ATEC) Shares Cross Below 200 DMAMarch 1, 2024 | finance.yahoo.comInsider Sell: EVP of Sales David Sponsel Sells 32,365 Shares of Alphatec Holdings Inc (ATEC)February 29, 2024 | finance.yahoo.comAlphatec Holdings Full Year 2023 Earnings: Revenues Beat Expectations, EPS LagsFebruary 28, 2024 | markets.businessinsider.comPositive Outlook for Alphatec Holdings Justifies Buy RatingSee More Headlines Receive ATEC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Alphatec and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/27/2024Today3/29/2024Next Earnings (Estimated)5/02/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryHealth Care Equipment Current SymbolNASDAQ:ATEC CUSIP02081G10 CIK1350653 Webwww.atecspine.com Phone(760) 431-9286Fax800-922-1356Employees839Year Founded1990Price Target and Rating Average Stock Price Target$23.63 High Stock Price Target$32.00 Low Stock Price Target$17.00 Potential Upside/Downside+71.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($1.55) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-186,640,000.00 Net Margins-38.70% Pretax Margin-38.76% Return on EquityN/A Return on Assets-27.93% Debt Debt-to-Equity Ratio6.54 Current Ratio2.86 Quick Ratio1.99 Sales & Book Value Annual Sales$482.26 million Price / Sales3.95 Cash FlowN/A Price / Cash FlowN/A Book Value$0.57 per share Price / Book24.19Miscellaneous Outstanding Shares137,980,000Free Float97,800,000Market Cap$1.90 billion OptionableOptionable Beta1.58 Social Links 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesMr. Patrick S. Miles (Age 58)Executive Chairman, CEO & President Comp: $1.59MMr. J. Todd Koning (Age 51)Executive VP & CFO Comp: $815.29kMr. David P. Sponsel (Age 45)Executive Vice President of Sales Comp: $848.19kMr. Craig E. Hunsaker (Age 60)Executive VP of People and Culture Comp: $909.33kMr. Eric Dasso (Age 51)Executive Vice President of Adjunctive Technologies Comp: $1MMr. Scott Lish (Age 45)Chief Operating Officer Mr. Tyson Eliot Marshall (Age 50)General Counsel & Corporate Secretary Mr. Ali Shorooghi (Age 38)Senior Vice President of Marketing Mr. Jonathan Allen (Age 64)Executive Vice President of Commercial Operations Dr. Luiz PimentaChief Medical OfficerMore ExecutivesKey CompetitorsGenMark DiagnosticsNASDAQ:GNMKLuminexNASDAQ:LMNXAtriCureNASDAQ:ATRCIntegra LifeSciencesNASDAQ:IARTCryoLifeNYSE:CRYView All CompetitorsInsiders & InstitutionsNomura Holdings Inc.Bought 14,870 shares on 3/27/2024Ownership: 0.011%Evan BakstBought 15,000 shares on 3/14/2024Total: $202,950.00 ($13.53/share)Vanguard Group Inc.Bought 778,976 shares on 3/11/2024Ownership: 3.909%Quentin S BlackfordBought 20,000 shares on 3/7/2024Total: $256,600.00 ($12.83/share)Tyson Eliot MarshallSold 9,225 sharesTotal: $121,401.00 ($13.16/share)View All Insider TransactionsView All Institutional Transactions ATEC Stock Analysis - Frequently Asked Questions Should I buy or sell Alphatec stock right now? 7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Alphatec in the last twelve months. There are currently 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ATEC shares. View ATEC analyst ratings or view top-rated stocks. What is Alphatec's stock price target for 2024? 7 brokerages have issued 1 year target prices for Alphatec's shares. Their ATEC share price targets range from $17.00 to $32.00. On average, they anticipate the company's stock price to reach $23.63 in the next year. This suggests a possible upside of 71.3% from the stock's current price. View analysts price targets for ATEC or view top-rated stocks among Wall Street analysts. How have ATEC shares performed in 2024? Alphatec's stock was trading at $15.11 at the beginning of the year. Since then, ATEC shares have decreased by 8.7% and is now trading at $13.79. View the best growth stocks for 2024 here. When is Alphatec's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024. View our ATEC earnings forecast. How were Alphatec's earnings last quarter? Alphatec Holdings, Inc. (NASDAQ:ATEC) released its quarterly earnings results on Tuesday, February, 27th. The medical technology company reported ($0.37) earnings per share for the quarter, missing the consensus estimate of ($0.28) by $0.09. The medical technology company had revenue of $138 million for the quarter, compared to analysts' expectations of $131.90 million. The firm's revenue was up 30.3% on a year-over-year basis. During the same period in the previous year, the business posted ($0.33) earnings per share. What ETFs hold Alphatec's stock? ETFs with the largest weight of Alphatec (NASDAQ:ATEC) stock in their portfolio include Jacob Forward ETF (JFWD), Innovator IBD 50 ETF (FFTY), SPDR S&P Health Care Equipment ETF (XHE) and Invesco Dorsey Wright Healthcare Momentum ETF (PTH).First Trust Nasdaq Lux Digital Health Solutions ETF (EKG). What guidance has Alphatec issued on next quarter's earnings? Alphatec updated its FY 2024 earnings guidance on Tuesday, February, 27th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $595.0 million-$595.0 million, compared to the consensus revenue estimate of $574.7 million. What is Pat Miles' approval rating as Alphatec's CEO? 19 employees have rated Alphatec Chief Executive Officer Pat Miles on Glassdoor.com. Pat Miles has an approval rating of 72% among the company's employees. 63.0% of employees surveyed would recommend working at Alphatec to a friend. What other stocks do shareholders of Alphatec own? Based on aggregate information from My MarketBeat watchlists, some companies that other Alphatec investors own include Macrocure Ltd. - Ordinary Share (MCUR), LinnCo (LNCOQ), California Resources (CRC), Sorrento Therapeutics (SRNE), Catalyst Pharmaceuticals (CPRX), (GBSN) (GBSN), Idera Pharmaceuticals (IDRA), Athersys (ATHX), Anavex Life Sciences (AVXL) and BioCryst Pharmaceuticals (BCRX). Who are Alphatec's major shareholders? Alphatec's stock is owned by many different retail and institutional investors. Top institutional shareholders include First Light Asset Management LLC (4.39%), Vanguard Group Inc. (3.96%), Vanguard Group Inc. (3.91%), Point72 Asset Management L.P. (2.20%), Cerity Partners LLC (1.38%) and Royal Bank of Canada (1.18%). Insiders that own company stock include Craig E Hunsaker, David H Mowry, David M Demski, David R Pelizzon, David Sponsel, Elizabeth Ann Altman, Evan Bakst, James L L Tullis, James L L Tullis, Jason Hochberg, Jennifer N Pritzker, Jennifer N Pritzker, John Todd Koning, L-5 Healthcare Partners, Llc, Mortimer Berkowitz III, Patrick Miles, Paul Segal, Quentin S Blackford, Scott Lish and Tyson Eliot Marshall. View institutional ownership trends. How do I buy shares of Alphatec? Shares of ATEC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ATEC) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders Alliance“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryAI Cracks Open Largest Untapped Energy Reserve on EarthBanyan Hill PublishingThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyFed launches fourth dollar overhaulStansberry ResearchMost important medical advance in 100 yearsThe Oxford Club Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alphatec Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.